Featured posts

0 3589

On Monday, the American Academy of Pediatrics asked the Drug Enforcement Administration (DEA) to reclassify marijuana as a less harmful substance in order to facilitate research of the substance for medical use.

“The AAP strongly supports research and development of pharmaceutical cannabinoids and supports a review of policies promoting research on the medical use of these compounds,” the AAP statement reads. The group recommends that the DEA reschedule marijuana from a Schedule I controlled substance to Schedule II.

The U.S has five different schedules for drugs under the Controlled Substances Act. The Schedule I label is reserved for the drugs that the DEA considers to have the highest potential for abuse and no “currently accepted medical use.”

Marijuana has been classified as Schedule I for decades. Other substances that are classified as a Schedule I substance with marijuana include heroin and LSD. Cocaine and meth are two substances that have classified as Schedule II substances. The government therefore believes that marijuana is more dangerous than cocaine and meth…which is crazy!

If the DEA reclassified marijuana as a Schedule II substance, it would not make marijuana legal, but it would ease the restrictions associated with researching the drug.

The AAP does not support marijuana legalization. In fact, the group has been strongly against the growing trend of marijuana legalization around the United States. The AAP, however, “strongly” supports the decriminalization of marijuana use and they encourage pediatricians to “advocate for laws that prevent harsh criminal penalties for possession or use of marijuana.”

The statement made yesterday is the first change to AAP policy on the issue since 2004. At that time, the group did not request a schedule change.

Who is responsible for regulating controlled substances?

The DEA is the federal agency primarily responsible for regulating controlled substances like marijuana. The Food and Drug Administration (FDA), and the National Institute on Drug Abuse (NIDA), are the two agencies that provide the DEA with recommendations pertaining to the appropriate level of restriction for various substances.

The FDA is already engaged in a review of the medical evidence surrounding the safety and effectiveness of marijuana. The evaluation was initiated due to a request from the DEA, following a number of citizens’ petitions asking for a review. According to the Controlled Substances Act, the government must consider eight factors when deciding the schedule under which a substance should be classified. These include its potential for abuse, the state of current scientific knowledge about the substance and its psychic or physiological dependence liability.

“FDA can’t comment on the suggestion to change the schedule for marijuana, as the latest FDA review of the issue — known as the 8-factor analysis — is currently ongoing, FDA press officer Jeff Ventura said Monday. “However, FDA agrees with the call by the AAP for rigorous scientific research into the uses of marijuana … [and] supports those in the medical research community who seek to study marijuana.”

In 2001 and 2006, the DEA made requests to the FDA for an evaluation of marijuana as a result of public petitions requesting a rescheduling. The results of these evaluations were not favorable for the marijuana community and the DEA regulators upheld the Schedule I label on marijuana. The FDA cited that there was insufficient research about marijuana’s effectiveness in treating a number of ailments.

The FDA has never advocated for the legalization of marijuana, but in 2014 it said in an update to its guidelines on marijuana that it is “aware that there is considerable interest in its use to attempt to treat a number of medical conditions, including, for example, glaucoma, AIDS wasting syndrome, neuropathic pain, cancer, multiple sclerosis, chemotherapy-induced nausea, and certain seizure disorders.”

The removal of the Schedule I label is the biggest catalyst for the marijuana industry. Once it is removed, researchers will be able to study marijuana and understand the medical benefits that are associated with the plant. This would speed up the drug approval process for pharmaceutical companies, which would in turn lead to incremental revenue growth for those companies.

0 2073

International Cannabis Business Conference in San Francisco, February 15 & 16

By all reports, The International Cannabis Business Conference of 2014 was an active success. Ladybud’s founder and publisher, Diane Fornbacher, was one of the industry professionals who spoke at the first International Cannabis Business Conference. With only a short time left until the second International Cannabis Business Conference, many industry insiders are preparing for a powerful and meaningful conference in San Francisco next month.

The second International Cannabis Business Conference event will be held at the Hyatt Regency San Francisco on Sunday, February 15th, 2015 and Monday, February 16th. Both days will entail well-respected and successful presenters, panels on relevant topics and the chance to network with some of the big power players in the marijuana business and activism worlds. currently, there are only 50 tickets available to the public. Early registration to the event for both days is $599 and $849 for those that want to upgrade and attend the VIP reception. Considering that the VIP reception allows for networking with some of the core speakers before the big meeting even begins, it may be a smart investment for some industry members.

Unlike many of the “networking and education” conferences about cannabis that seem to be popping up all over the place, the ICBC has real relations and ties to ongoing activism efforts and has shown dedication to conscientious capitalism and proper businesses practices in an industry often polluted by snake oil salesmen and quick-rich-quick con artists. In fact, many of their excellent speakers are people vigorously working to rid prohibition, such as Dr. Carl Hart, Ph.D,who recently testified in front of a federal judge in California that marijuana should not be a Schedule I substance. Other key points from their San Francisco speaker roster include:

Dale Sky Jones

Rick Steves

Doug Fine

Amber Senter

Steve DeAngelo

Debby Goldsberry

As their choice of speakers makes amply clear, the ICBC’s focus on the first day of the event this year will be activism. Given how closely many are eying California for complete legalization efforts, this conference coming at the perfect time. Those wishing to help influence policy as it develops or those hoping to create or build a marijuana-related business in the recent developing legal markets will definitely benefit from speakers who have been fighting on the forefront for decades in some cases.

The second day of the ICBC’s San Francisco event will tune in more on business; in addition to presentations by successful cannabis business men and women, there will be panels on marijuana businesses and dispensaries in particular which will surely be helpful to those considering getting involved in the California Green Rush.

Tickets for admission to the 2015 San Francisco International Cannabis Business Conference are currently available for sale online as of the publication of this article (click here to purchase). You can follow updates on the event by liking the Facebook page for the International Cannabis Business Conference here.



    1 3421
    Marijuana Stocks

    By Juliette Fairley

    With experience in criminal defense, constitutional law, workplace drug policy and intellectual property, lawyers are at the forefront of the national movement to legalize marijuana. Here’s a list of five lawyers to watch in 2015 as legal medical and recreational marijuana continues to sweep the country.

    Douglas Sorocco -Educated as a biochemist, Douglas Sorocco practices intellectual property law related to cannabis technologies. “The cases I represent have to do with strains and chemical compounds that are being discovered and used for medicinal treatments,” said the Oklahoma based Sorocco. “We do the patent application and litigation for it.” The majority of Sorocco’s clients are pharmaceutical and life sciences companies from outside the U.S., such as Canada, the Netherlands and Uruguay. “The hot button issue is whether or not the federal government will allow patents on strains and if so what is going to be the amount of evidence or information they will require to grant those patents,” said Sorocco.

    Michael Minardi – Amendment 2 would have legalized marijuana for medical purposes in Florida had it passed on November 4 but it didn’t. As a result, Michael Minardi expects to continue to reduce the sentences of his marijuana using clients in West Palm Beach who are typically over 40 years old and suffer from conditions, such as AIDS, COPD, fibromyalgia and glaucoma. “The denial of Amendment 2 will not change my practice of defending patients who have been arrested for using cannabis as medicine and are presenting a medical necessity defense,” Minardi said. Minardi is also the legal director of the National Organization for the Reform of Marijuana Laws (NORML)

    Danielle Urban – Because impairment cannot be easily tested, employers worry that workers who use marijuana in their free time will harm themselves or others in the workplace, creating liability issues. However, zero tolerance corporate policies pose a special set of legal concerns. “Many employers are terrified they will be sued if they have zero tolerance policies and fire someone with a medical card,” said Urban, a labor and employment attorney in Colorado. “More research is needed to determine what constitutes impairment for work-safety purposes and the long-term health effects of marijuana use.” Urban said. Because drug policy varies from state to state, national employers are left with a patchwork of marijuana drug testing policies to figure out. “Some employers choose to stay out of their employees’ personal lives and have suspended testing because they don’t know what to do about marijuana use,” said Urban.

    Mara Felsen- Professional experience in constitutional, criminal and administrative law helped to create Mara Felsen’s unique legal perspective but it was a car accident that lead the San Diego attorney to turn her personal experiences as a medical marijuana patient into a cannabis law specialty.

    Robert Hoban – The Drug Enforcement Administration announced this month that it will not pursue for prosecution hemp based products with THC levels less than .3 percent. As a result, CBD and hemp attorney Robert Hoban predicts there will be a large push in the pot marketplace to develop methods to lower the THC content, which naturally rises during processing and purification process. “This will hedge any federal government interference even though the product is lawful and has higher levels of THC of .8 to 2.8%,” said the Denver-based Hoban who represents a number of the nation’s largest hemp and CBD importers, producers, processors and suppliers.

    1 2838

    No matter who you are talking to nowadays, if Colorado is being talked about, pot will soon come up in the conversation. Moving into the second full year of legal recreational pot has people in the state and across the country looking for ways to educate people on marijuana, especially parents.

    Over 400 voters in Mesa County were given a survey this summer to get a sense for what they think about marijuana legalization. The results surprisingly showed that more parents were in support of legal pot than those without kids.

    “I don’t want my kids growing up thinking that its okay to do,” said Shannon Furo.

    For Furo and her family, marijuana legalization wasn’t something they thought twice about when they moved to Colorado. The subject didn’t cross their minds until after they moved to the state and heard a commercial on the radio from a new campaign in the state to educate people on pot. Furo is like many moms who want to protect their kids from growing up around pot. But there are other parent’s with opinions that differ from Furo’s

    Mom Tani Lambert is under the belief that legal weed is an okay thing, because she thinks that the taboo nature of pot makes the idea of trying it more appealing to younger ones.

    “As a parent, if kids don’t look at it as a big thing then they’re not going to be as compelled to try and do it behind your back,” Lambert said.

    Marijuana legalization in Mesa County failed by a very narrow margin. The survey of voters showed that 46% of people had thought legalization was a good idea, with only 1% more thinking it was a bad one.

    “That was concerning to us- about what’s the message being sent down to the kids and are they being told that this is a big deal, that this is important decision to make, ” said Dan Rubinstein with the District Attorney’s office.

    Anti-pot advocates make that point that children pickup on what adults are talking about at a very young age. They also retain a lot of what they hear on TV and the radio.

    Colorado launched a controversial campaign last year called “Don’t Be a Lab Rat”, which was focused on the uncertainty of the effects marijuana has on youth. This year the state’s program is instead focused on educating adults about responsible marijuana use, using what they are calling “relatable methods”. Some are worried about how this style of education may send the wrong message to children.

    With the results from the 2014 survey of Mesa County voters, the county is now motivated to start their own campaign.

    “Were working on using the state’s message a little bit but we’d like to shape our own message,” Rubenstein said. “While the numbers are pretty well split, it seems to be something that I think education may change that.”

    1 694
    Cannabis Stocks

    OXIS International Inc. (OXIS: OTCPK) is a biotech company that develops and commercializes innovative drugs of therapeutic molecules including cannabinoids. The company is focused on creating medicines that are derived from the cannabis plant, which will improve daily life for people all over the world. OXIS can be a winner due to the following reasons: 1) OXIS signed an agreement which allows them to license certain assets for the treatment of Multiple Myeloma and simultaneously initiated a consulting agreement with University of Pittsburgh’s Professor, Dr. Xiang-Qun Xie, 2) OXIS is led by a management team that has a proven track record and years of experience, 3) They have a first mover advantage in a high growth industry, but 4) They are the epitome of a risk vs reward company.

    Licensed assets for the treatment of Multiple Myeloma and entered agreement with Dr. Xie

    On January 12, 2015, Oxis International’s subsidiary, Oxis Biotech, Inc., executed definitive agreements that gave the company licensing rights to certain assets for the treatment of Multiple Myeloma. The license provides the company with an exclusive worldwide license to develop and commercialize therapies for the treatment of Multiple Myeloma. OXIS simultaneously initiated a consulting agreement with University of Pittsburgh’s Professor, Dr. Xiang-Qun Xie, who joins the company as a consultant and as a member of the Science Advisory Board to further develop the assets licensed to Oxis Biotech, Inc.

    OXIS CEO Tony Cataldo stated, “Oxis is honored to have Dr. Xie and his patented technology as an integral part of our strategy to develop high valued patented assets for the treatment of Multiple Myeloma. I wanted to leverage Dr. Xie’s significant experience and technologies, much the same way I did when I acquired highly valued patents from the NCI (NIH) for stage 4 Melanoma from the National Cancer Institute to form Lion Biotechnologies, Inc. (LBIO)”.

    Led by a strong management team

    Many cannabis companies are led by sub-par management teams and are comprised of individuals that have a proven track record….of criminal activity. That is the furthest thing from the truth when you look at the management team at OXIS International. OXIS is led by a management team that has proven track record of success. One of the best things that their management team did was put together a strong team on their Board of Directors.

    OXIS’s CEO, Anthony Cataldo served was the Chairman/CEO of Genesis Biopharma, inc., now known as Lion Biotechnologies, Inc., (LBIO) from February 2011 to June 2013. Mr. Cataldo has extensive experience in the biotechnology sector having served as Chairman/CEO of several biotech companies including: MultiCell Technologies, Inc., Calypte Biomedical Corporation, and Senetek, PLC.

    The company’s CFO, Steven Weldon, previously was the CFO of GrowBLOX (GBLX: OTCQB), a well-known cannabis company. Mr. Weldon is a certified public accountant and he received his Bachelor of Science degree and his Masters in Business Administration from Florida Southern College

    Involved in a high growth industry

    One of the biggest beneficiaries of the marijuana boom is going to be the pharmaceutical sector. Some of the pharmaceutical companies are starting to look into the benefits associated with the cannabis plant, but they haven’t cracked the surface. OXIS is looking into developing treatments for illnesses that have not been researched by the major marijuana pharmaceutical companies, such as GW Pharmaceutical (GWPH: NASDAQ) or I NSYS Therapeutics, Inc. (INSY: NASDAQ). This gives them a first mover advantage.

    For this reason OXIS has the rare opportunity to be one of the biggest winners in the marijuana sector. The team that they have put in place and the technology they have should enable them to successfully create a variety of treatments, starting with Multiple Myeloma.

    Nothing is a sure thing

    While the reward for OXIS can be huge, so is the risk. Many pharmaceutical companies have to jump over major hurdles in order to be successful. The same goes for OXIS. The process of developing a drug treatment is extremely expensive and very often the company needs to raise capital in order to proceed with clinical testing. When companies need to raise capital, their stock is usually diluted. This is one of the risks that OXIS faces. While the company did raise money during mid-2014, it most likely will not be enough.

    7 8723
    marijuana stocks

    After a wild year for marijuana stocks in 2014,

    many of our viewers and members contacted us asking for our opinion and outlook for 2015. So what did we do? The MarijuanaStocks.com team sought out the advice of an experienced, professional hedge fund trader to see how he was maneuvering this market. The following is his report. Enjoy. We sure did.

    Trade and Run or Buy and Hold?

    Marijuana Plant or Biotech?

    Many people have asked me what the best way to invest in the marijuana industry is. My response is not one specific company but rather an overall strategy based on different niche sectors that has allowed me to profit quite handsomely from a market overflowing with uncertainty, regulation and volatility. Understanding how each niche sector is effected by the evolving industry and how investors react regarding the different risk factors of each sector is key.

    I compare the Marijuana Industry to the Internet Boom. The similarities from an investment stand point are eerily similar. Although the Internet was not bound by regulation, the volatility and investor craze was unlike anything I’ve ever seen in my career. But you could NOT just simply put your money into any new Internet company and not check it for a year or two. Maybe 90% of the Internet IPOs failed. But that doesn’t mean there wasn’t massive amounts of money to be made trading them. Then, as the industry developed, matured and the potential of the Internet was fully understood by investors, the Apples, Microsofts, and Yahoos began to separate themselves from the rest of the pack. And those were the companies that you could put your money in and not look at it for years to come.

    But when an industry is just starting, as the marijuana sector literally is before our eyes, it is nearly impossible to identify the future leaders when there is so much speculation and outside factors like regulatory issues state by state and by the overall government. That is why I am not holding one single “marijuana company” yet. I am trading them. Why? Because any company that is directly affected by regulation of the cannabis plant is not a safe long-term investment, yet. And I stress the word yet because eventually the industry will mature enough to where a select few marijuana companies will be a buy and hold. But for now, trade the volatility. Get in and get out. During the last 8 months, I am averaging 2-3 day holding periods on cannabis stocks.

    Now, there is, however, another niche sector of the cannabis revolution that has been a buy and hold. And that is because it is in no way affected by the regulation of the actual marijuana plant. That sector is biotech. Companies using cannabinoid structures to produce various drugs and medicines to treat specific ailments and hopefully achieve FDA approval. To date, this is the only sector of the cannabis revolution, in my opinion, that has been a safe long term investment.

    Volatility levels are nowhere near like what we see in marijuana companies. And that is because the success of a biotech company’s stock is much more determined by the company’s ability to execute on their business plan. A marijuana company can execute their business plan quickly and efficiently and receive proper licensing but will still see negative performance if a major regulatory event hinders the industry. Similar to the overall sell-off we saw in marijuana companies when Florida declined the use of medical marijuana. This is why you must trade these companies quickly. There are too many outside factors that will affect your investment.

    Biotech vs. Marijuana

    When looking at biotech companies operating in the cannabis space, you see a very steady and solid long term uptrend. On the other hand, when looking at marijuana companies dealing with the plant or ancillary products, you see a distinct long term downtrend with several quick momentum building trades mixed in between. Here are a few examples of what I’m talking about:


    There are two clear leaders in the cannabis revolution and they are both biotech companies. Neither company actually touches the marijuana plant itself and are not held to the same restrictions and regulatory exposure. This has allowed these two companies to execute on their business plans free of outside risk and uncontrollable factors making them safe long term investments to this point. In addition, the biotech sector is the only niche cannabis sector to see institutional support giving the retail investor a sense of security. Now, of course every stock will have its ups and downs, but the point to take from this is that the biotech sector is the only sector of the marijuana revolution still holding significant gains over the past 12 months or longer.

    GW Pharmaceuticals (GWPH)

    gwph marijuana stock

    INSYS Therapeutics Inc. (INSY)


    GWPH and INSY are both sporting solid, consistent uptrends while posting gains well over 500% for those who bought and held over the last 12-24 months. The biotech cannabis sector has proven to be the only niche sector to maintain a long term uptrend making it the only sector, to date, worth holding.


    Companies dealing directly with the marijuana plant and/or its ancillary products, have been extremely volatile providing excellent trade opportunities. However, anyone who used the buy and hold model in this sector is left with near worthless investments. This is a direct result of the unknown risk element involved with regulatory actions and investors trying to understand how the state by state approval/denial of medical/recreational marijuana will effect a company’s business model.

    Medbox Inc. (MDBX)


    Medbox would be placed in the ancillary products niche sector. As you can see, MDBX has experienced a severe downtrend over the last 12 months. However, there have been several very profitable quick trades throughout 2014. Take your profits and move on. Anyone who left their money in MDBX for an extended period of time saw their investment melt away.

    Medical Marijuana, Inc. (MJNA)


    Medical Marijuana, Inc. has experienced a distinct downtrend for the past 12 months with a couple profitable trades mixed in between. Throughout the entire year, there was only one instance where it was safe to hold MJNA for longer than 4 days.

    Cannabis Science Inc. (CBIS)


    Cannabis Science, too, has been in an overall downtrend for the past 12 months with a few profitable trades throughout.

    The list of marijuana companies in a downtrend goes on and on with many charts depicting a very similar picture as the ones above. This even stretches into the vapor industry, another ancillary marijuana sector.


    The marijuana industry is growing, but is still in its infancy stage. Similar to what we saw during the Internet Boom, as time progresses I expect to see companies separate themselves from the pack while others fade away into oblivion. Until the outside, uncontrollable risk factors are not as much of a catalyst, marijuana companies will remain nothing more than quick trades for me. But I stress, I am very positive on the future of this industry. I simply think it is still young. As the sector develops, the opportunity for long term buy and hold investments will become clearer.

    But as of today, my buy and hold strategy will be in the biotech cannabis space as they are not subject to the regulatory exposure that has proven detrimental to a company’s stock. I will continue to trade the momentum and volatility of marijuana companies because they do provide excellent liquidity and profitable opportunities. But I will likely not hold a position longer than 4-5 days at a time.

    3 1444


    0 2654

    A group of scientists with the University of Sydney made the announcement that they may have stumbled upon what would be a fourth species of cannabis. The discovery was made in the Blue Mountains of Australia.

    Scientists discovered the plant in 2010 when a group of people hiking in the mountains found a plant that resembled cannabis. After the discovery tests were done on the plant with the results proving it to be cannabis.

    “When we first received the plant, we were very skeptical about its relation to cannabis,” says researcher Christopher Pool. “It has somewhat similar growth structure but the leaves look nothing like cannabis leaves.”

    Testing on the plant show that even with the different looking leaves, the plan was indeed cannabis. This new species is resistant to freezing temperatures. The shape of the plant is more like a shrub than the normal archetypal candelabra like is common with most other strains of cannabis.

    There is excitement with cannabis growers worldwide as word spreads of the new discovery. Some growers have even offered the researchers $2000 for a single seed. The researchers unfortunately don’t have any seeds, just the one plant that was found, and they have been unable to find another like it.

    There is a 10,000 reward being offered to anyone who has any information on the location of addition plants of this species.

    1 2718

    HLN talk show host Nancy Grace brought rapper 2 Chainz onto the show Tuesday night to discuss pot. But really it seemed it was more about attacking his character, and being down right racist at times.

    Her interview started off with a introduction of 2 Chains, which included mentioning that he is also known as “Titty Boi”, as well as his real name which is Tauheed Epps.

    At first it seemed she was complementing him, “I know your persona is different than your rap persona,” Nancy said. She also brings up his 4.0 GPA in college and the scholarship he received to get his degree. But then she launches into a full on attack. It’s hard to tell whether her attack is on 2 Chainz, pot or rap music.

    Grace shows viewers video footage and says, “I’ve seen video of you smoking a big fat doobie.”

    One of Nancy’s shinning moments in the interview is when she shows multiple (very grainy and hard to decipher) videos of parents supposedly getting their young children high and using the examples to implicate that all people who smoke pot are child abusers.

    “I don’t think you can put an umbrella on the community you just named,” 2 Chainz tells her. “I just feel like you can’t use these particular stories to define everybody that has recreational use.”

    Possibly the best line of the interview was Grace’s response, “I’m not defining everybody. So don’t put me in that pot and stew me.”

    Grace goes on to argue that legalization puts pot into the hands of everyone and how that would make even more people act irresponsibly.

    2 Chainz responds with, “I’m not sure if you know, but everybody can get their hands on pot right now, whether it’s legal or not.” He also brings up the fact that everyone can access alcohol right now and people tend to act a lot worse with that.

    Really to get the full insanity of the interview, you need to watch it for yourself.

    0 780

    Attention on marijuana stocks has begun to increase since uncertainty last year during midterm elections spawned a consolidation period just before the close of the year.

    As the new outlook for 2015 became more positive for companies in the sector, the January effect has had its way with many of these stocks and several continue to see new highs.   With major investment coming into the industry, there’s no doubt that this will continue to be a topic of interest in the coming year.  Just recently Paypal co-founder Peter Thiel invested in the marijuana industry through a minority stake in Privateer Holdings (through his own fund, The Founders Fund).  Seemingly the marijuana industry’s biggest investor thus far has created a domino effect within the public markets, giving more confidence to otherwise prudent investors.

    Oxis Inernational Inc (OTC:OXIS) recently announced that it had executed a worldwide exclusive patent licensing for certain assets for the treatment of Multiple Myeloma and initiated a consulting agreement with University of Pittsburgh’s Professor, Dr. Xiang-Qun(Sean)Xie.  Dr. Xie is one of the foremost cannabinoid research scientists in the world and boasts a track record of success that’s a mile long.  The license agreement provides Oxis Biotech, Inc an exclusive worldwide license to develop and commercialize therapies for the treatment of Multiple Myeloma.

    Over the last 10 days, OXIS has managed to reach two major and very important milestones, which may have been cause of so much market attention building around this company.  They went from caveat emptor status on OTCMarkets to a Current PinkSheet after getting all of the filings up to date.  Furthermore Oxis entered into this recent licensing agreement.  Since mid-December not only has the stock been on a very consistent upward trend but it has also seen highs of nearly $0.04; coming up from lows of just over a penny.

    Advanced Cannabis Solutions (OTC: CANN) is a service provider to businesses in the cannabis industry.  Recently the company announced that it has signed a Master Services Agreement with New York based Spector Group, one of the nation’s leading architecture, interior design and master planning firms, for the build out of its multi-tenant office building in Denver, to be known as “The Greenhouse.” Robert Frichtel, Chief Executive Officer of ACS, commented, “We are very glad to have Spector Group come on board with this project. As an established and highly experienced firm, we are confident that Spector will bring our vision of The Greenhouse to life quickly and with a minimum of difficulty.”

    Over the last 2 weeks, Advanced Cannabis has been on a warpath for big gains.  The stock opened the year at $1 and has since jumped more than 400% to highs on Tuesday of $4.50. Similar to Oxis just a few weeks ago, Advanced Cannabis is reporting a Caveat Emptor status on OTC Markets.

    United Cannabis Corporation (CNAB) has also come across the radar of many marijuana stock investors.  This month the company announced that it has signed a consulting and licensing agreement with FoxBarry Farms, LLC, whereby FoxBarry will be the exclusive licensee and distributor of United Cannabis branded medical marijuana products in the State of California.

    FoxBarry has earmarked $30 million to fund all phases of the California state-wide program. The Company will receive $200,000 in prepaid royalties for exclusive licensing rights in the State of California and the first location will be located in Northern California; operations are expected to begin in the next 30-45 days.  During the matter of a few days, United Cannabis’ stock price has been on a bull run.  Since opening the year around $0.70, this stock has seen an increase in volume and a jump in price by roughly 91% in the matter of just a few weeks.  Sentiment remains high (no pun intended) across the marijuana sector and these companies have garnered more interest from traders and investors alike.

    About marijuanastocks.com

    MarijuanaStocks.com is the leading web destination for all things cannabis. Investors can find marijuana related financial, medical, legal, and social news anytime day or night. Writers are invited to submit cannabis related articles for publication.

    Legal Disclaimer

    Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. DAMJ VENTURES LLC which owns www.MarijuanaStocks.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release.

    DAMJ VENTURES LLC, which owns www.MarijuanaStocks.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. DAMJ VENTURES LLC which owns www.MarijuanaStocks.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

    Contact Information:



    Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

    We are your #1 source for all things Marijuana Stocks, Subscribe Below!

    Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
    Ad Placements